A carregar...
Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism
BACKGROUND: Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin‐like growth factor 1 (IGF‐1) and improves insulin sensitivity in cats with HS when administered as a short‐acting preparation. OBJEC...
Na minha lista:
| Publicado no: | J Vet Intern Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5354018/ https://ncbi.nlm.nih.gov/pubmed/28145031 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvim.14662 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|